

Exciting New Developments in Pediatric Gastroenterology

08/01/18 Expiration Date: 12/01/18

Jointly provided by



and



Intended Audience

Nurse Practitioners, Nurse Midwives and Physician Assistants in acute and primary care roles.

Learning Objectives

Upon completion of this activity, the participant should be able to:

- Describe how to use on-line decision support tool for celiac disease testing.
- Discuss new therapies patients are choosing for inflammatory bowel disease including biologics, diet, and cannabis.
- Explain why a new type of endoscopy, trans-nasal endoscopy or TNE, is rapidly gaining popularity

Statement of Need

New areas of pediatric gastroenterology will be highlighted. Learn how to use an on-line decision support tool for celiac disease testing. New therapies for pediatric IBD will be discussed, including use of enteral nutrition, SCD diet, and new biologics. Research on cannabis use by adolescents and young adults with IBD will be reviewed. A new type of endoscopy, the new trans-nasal endoscopy procedure will be described, as well as why it is gaining in popularity and how it is used in the clinical setting.

Accreditation Statement(s)



In support of improving patient care, this activity has been planned and implemented by Dannemiller and National Nurse Practitioner Symposium. Dannemiller is jointly accredited by the Accreditation Council for Continuing

Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Dannemiller designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners



This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP)

through the joint providership of Dannemiller and National Nurse Practitioner Symposium. Dannemiller is accredited by the American Association of Nurse Practitioners as an approved

provider of nurse practitioner continuing education.

Provider number: 090419. This program is accredited for 1.5 contact hour(s) which includes 0.25 hours of pharmacology.

Nurses

Dannemiller designates this enduring material for 1.5 contact hour(s).

Method of Participation

Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive your contact/CE hours view the presentation video, and complete and pass a 10-question test on the presentation content (80% is considered passing).

Credit is provided through December 1, 2018. No credit will be given after this date. If you attended the 2018 National Nurse Practitioner Symposium, these enduring materials hours are complimentary and separate from the contact/CE hours you received at the live meeting. If you did not attend the 2018 National Nurse Practitioner Symposium, the cost is \$5 per test attempt. If you are not successful in passing a test on first attempt, you may retake the same test after a 24 hour grace period, which allows you time to review the presentation video again.

Faculty

Edward Hoffenberg, MD; Medical Director, Pediatric Inflammatory Bowel Diseases Center, Children's Hospital Colorado; Aurora CO and Professor, Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus; Aurora CO

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME/CE activity must disclose all financial relationships they have with a commercial interest.

The following faculty members have no financial relationships with commercial interests:
Edward Hoffenberg, MD

Bernard Abrams, MD content reviewer; Jennifer Hodge, Project Manager, Dannemiller; and NNPS coordinating staff have no financial relationships with commercial interests.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

Off-label statement

Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically

and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or National Nurse Practitioner Symposium. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject